Publications by authors named "L Sridharan"
Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions.
Eur Heart J Acute Cardiovasc Care
October 2024
Article Synopsis
- The Shock Academic Research Consortium (SHARC) created standardized definitions for cardiogenic shock (CS) to improve classification in clinical settings and studies.
- A study using these definitions observed a total of 8,974 patients, finding that 65% had isolated CS, with significant variations in causes such as acute myocardial infarction and heart failure.
- Results indicated that patients with mixed CS had the highest mortality rate (48%), while acute-on-chronic heart failure presented the lowest (25%), highlighting the need for targeted treatment strategies based on CS subtypes.
Article Synopsis
- Limited research exists on the causes of death in patients with cardiogenic shock (CS), prompting a study by the Critical Care Cardiology Trials Network from October 2021 to September 2022.
- Among 1068 cases studied, 337 patients (31.6%) died, and 82.2% of these deaths were attributed to cardiovascular issues, primarily persistent cardiogenic shock.
- Key findings showed that patients with prior cardiac arrest had higher risks of dying from anoxic brain injury or arrhythmia, and those receiving temporary mechanical circulatory support (tMCS) often succumbed to persistent shock.
Interhospital Variation in Admissions Managed With Critical Care Therapies or Invasive Hemodynamic Monitoring in Tertiary Cardiac Intensive Care Units: An Analysis From the Critical Care Cardiology Trials Network Registry.
Sarah Donnelly Christopher F Barnett Erin A Bohula Sunit-Preet Chaudhry Meshe D Chonde Lakshmi Sridharan
Circ Cardiovasc Qual Outcomes
January 2024
Article Synopsis
- * A study analyzed data from nearly 18,000 CICU admissions across 34 hospitals to assess the use of CCRx and its association with in-hospital survival, finding disparities in patient acuity and therapy utilization among hospitals.
- * The findings revealed that patients in hospitals with higher CCRx usage tended to have more severe conditions and higher comorbidity rates; however, adjusted mortality rates did not significantly differ based on CCRx levels, implying patient factors primarily influence therapy variations.
Durable left ventricular assist devices (LVADs) are a virtually limitless advanced therapy option for an increasingly growing population of patients with end-stage advanced heart failure. As of 2019, 30% to 40% of all patients diagnosed with heart failure were categorized as New York Heart Association class III or IV. In 2018 more than 3.
View Article and Find Full Text PDF